Clinical trials: Coagulation, Blood
- Condition Coagulation, Blood
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Hemophilia A, Hemophilia B
A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of ALN-AT3SC in healthy volunteers and Hemophilia A or B patients.
- Trial name
- NCT02035605
- Testing
- ALN-AT3SC, Sterile Normal Saline (0.9% NaCl)
- Where
- 14 sites in United States, Bulgaria and 3 more
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Sanofi
Idiopathic Thrombocytopenic Purpura
A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501
This is a study in healthy subjects. There are two parts to the study. In the first part of the study each subject will receive a single 10mg dose of each of the four formulations of E550.
- Trial name
- NCT01549054
- Testing
- 10-mg dose of E5501 2G tablet, 10-mg dose of E5501 cyclodextrin oral solution, 10-mg dose of E5501-P21% powder
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Purpura, Thrombocytopaenic, Idiopathic
Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment
The main purpose of this study is to compare how one 50 mg tablet of SB-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe kidney problems.
- Trial name
- NCT00442871
- Testing
- eltrombopag
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Skin Health, Skin Aging of Face and Hands
The Effect of Nutritional Supplementation on Actinic Purpura: A Pilot Study
Purpura is a macule or papule of blood in the skin. It is mostly seen in mature skin that is often prone to significant bruising.
- Conditions
- Skin Health, Skin Aging of Face and Hands, Healthy, Ecchymosis
- Trial name
- NCT06840574
- Testing
- Cyruta Plus: A Whole-Food Based Vitamin C supplement containing organic buckwheat (aerial parts) juice powder, organic buckwheat flour, bovine adrenal Cytosol™ extract, oat flour, honey, ascorbic acid, Low Dose Vitamin C, High Dose Vitamin C
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Standard Process Inc.
Anticoagulation Reversal
Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban
This study will evaluate the establishment of anticoagulation ("re-anticoagulation") of subjects with edoxaban following reversal by PER977 and will identify a dose regimen of PER977 that reverses the effects of edoxaban for up…
- Trial name
- NCT02207257
- Testing
- PER977, Edoxaban
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Deep Vein Thrombosis Leg, Stroke (in Patients With Atrial Fibrillation)
A Healthy Volunteer Study to Investigate the Blood Concentrations, the Effect on Blood Clotting and the Safety of Multiple Doses of DPOC-4088 Tablets in Different Doses.
A study to investigate the concentrations of a new drug DPOC-4088 in blood, and to study the effect of this drug on blood clotting parameters.
- Trial name
- NCT01647620
- Testing
- DPOC-4088
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Diakron Pharmaceuticals
Hemostasis, Oral Contraceptive
A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women
This study is being conducted to evaluate the impact of a 91-day extended cycle oral contraceptive compared to two 28-day oral contraceptive regimens on hemostatic parameters in healthy women.
- Trial name
- NCT01252186
- Testing
- 91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive, 28-day Desogestrel Oral Contraceptive
- Where
- 24 sites in United States, Italy
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- Teva Women's Health
Haemophilia A
A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and Cartridge
Novo Nordisk is developing the study medicine Mim8 for the treatment of haemophilia A. The study aims to show similar levels of Mim8 in blood when using a new pen injector, called DV3407-C1 pen injector, and when using a syringe…
- Trial name
- NCT05681845
- Testing
- NNC0365-3769 (Mim8)
- Where
- Germany
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
The Effect of Strenuous Exercise on Haemostasis.
The Effect of Strenuous Exercise on Coagulation.
Many studies have shown that vigorous exercise increases the risk of developing vascular thrombotic events and can result in sudden death during or immediately after exercise.
- Trial name
- NCT02048462
- Where
- Netherlands
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Synapse bv
Healthy
Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers
To compare with placebo the anticoagulant activity of three dosages of BIBT 986 on parameters of coagulation, platelet activation and inflammation in a model of tissue factor triggered activation of the coagulation system; to…
- Trial name
- NCT02259881
- Testing
- Low dose of BIBT 986 CL, per i.v. infusion, Medium dose of BIBT 986 CL, per i.v. infusion, High dose of BIBT 986 CL, per i.v. infusion
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin
PER977 administration following a single dose of enoxaparin
- Trial name
- PER977 (NCT02206100)
- Testing
- PER977, enoxaparin
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Hemophilia A or B With Inhibitors
A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male
A Phase 1, randomized, single-blind, placebo-controlled, single dose, dose-escalation study to assess the safety, pharmacokinetic and pharmacodynamic profile of subcutaneous administration of a long-acting recombinant factor VIIa…
- Trial name
- NCT02919800
- Testing
- MOD-5014
- Where
- Israel
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- OPKO Health, Inc.
Haemophilia A
A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy Men
This study will test how different doses of study medicine (Inno8) work in the healthy men. The purpose of this study is to prove safety of Inno8 in healthy men, which will support further development of Inno8 in people with…
- Trial name
- VOYAGER1 (NCT06649630)
- Testing
- NNC0442-0344 A
- Where
- 2 sites in Germany
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Hemophilia a, Hemophilia B
The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B)
The purpose of this study is to investigate the safety and activity in the body of a new drug called SerpinPC. The study will be split into 7 parts: Part 1a will be conducted in healthy male volunteers in the UK (up to 15) and…
- Trial name
- NCT04073498
- Testing
- SerpinPC
- Where
- 3 sites in Georgia, Moldova and 1 more
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- ApcinteX Ltd
Idiopathic Thrombocytopenia Purpura
A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects
The purpose of this study is to evaluate the relative bioavailability (BA) of two lots of E5501 40 mg tablets administered twice as single oral doses to healthy subjects.
- Trial name
- NCT01289509
- Testing
- E5501, Drug: E5501
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Haemophilia A
A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People
The purpose of this study is to test a new medicine called Inno8. The study will test how eating and drinking before and after taking Inno8 affects how well it is absorbed in the stomach. The study consists of four arms.
- Trial name
- NCT07238816
- Testing
- NNC0442-0344 A
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Hemophilia A, Healthy Adult Participants
A First-in Human Study of ARD001 in Healthy Volunteers and People With Hemophilia A
This study is evaluating ARD001, an investigational medicine being developed for the treatment of hemophilia A. In Phase 1, healthy adult participants will receive a single dose of ARD001 or placebo to assess its safety and…
- Trial name
- NCT07787091
- Testing
- ARD001
- Where
- Singapore
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Arditus Pte Ltd
Heart Disease, Focus is on Testing Performance of CORA Hemostasis System.
Equivalency Study of the TEG and CORA Hemostasis Systems
This study is being performed to obtain data about the CORA system, a new device that is currently being tested and is not yet cleared for sale in the United State by the Food and Drug Administration (FDA).
- Trial name
- NCT01790386
- Where
- 4 sites in United States
- Volunteers
- 465 people, healthy volunteers welcome
- Sponsor
- Coramed Technologies LLC
Venous Thrombosis
Phase I Study of Direct Coagulation Factor Xa Inhibitor SYHA136 Tablets in Chinese Healthy Volunteers
The trial used single-center, randomized, double-blind, placebo-controlled, single-dose ascending study. The trial planned to enroll fifty-six healthy volunteers.
- Trial name
- NCT04036656
- Testing
- SYHA136 0.5 mg, SYHA136 1 mg, SYHA136 2.5 mg
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Coagulation, Therapeutic Uses
Hemostatic Closure of Femoral Artery Access Site, Using the QuickClose Design 9 System
The QuickClose Design 9 is a prospective, non randomized study, to evaluate the safety and efficacy of the QuickClose design 9 closure device.
- Conditions
- Coagulation, Therapeutic Uses, Pharmacologic Actions
- Trial name
- NCT01121510
- Testing
- closure device
- Where
- Israel
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- CardioDex